Disease-regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis
- PMID: 25028707
- DOI: 10.1136/annrheumdis-2014-205223
Disease-regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis
Abstract
Objectives: Rheumatoid arthritis is a chronic destructive autoimmune disease, but the course is unpredictable in individual patients. An attractive treatment would provide a disease-regulated therapy that offers personalised drug delivery. Therefore, we expressed the anti-inflammatory interleukin-10 (IL-10) gene under the control of inflammation-dependent promoters in a mouse model of arthritis.
Methods: Proximal promoters of S100a8, Cxcl1, Mmp13, Saa3, IL-1b and Tsg6 were selected by whole-genome expression analysis of inflamed synovial tissues from arthritic mice. Mice were injected intraarticularly in knee joints with lentiviral vectors expressing a luciferase reporter or the therapeutic protein IL-10 under control of the Saa3 or Mmp13 promoter. After 4 days, arthritis was induced by intraarticular injection of streptococcal cell walls (SCW). At different time points after arthritis induction, in vivo bioluminescent imaging was performed and knee joints were dissected for histological and RNA analysis.
Results: The disease-regulated promoter-luciferase reporter constructs showed different activation profiles during the course of the disease. The Saa3 and Mmp13 promoters were significantly induced at day 1 or day 4 after arthritis induction respectively and selected for further research. Overexpression of IL-10 using these two disease-inducible promoters resulted in less synovitis and markedly diminished cartilage proteoglycan depletion and in upregulation of IL-1Ra and SOCS3 gene expression.
Conclusions: Our study shows that promoters of genes that are expressed locally during arthritis can be candidates for disease-regulated overexpression of biologics into arthritic joints, as shown for IL-10 in SCW arthritis. The disease-inducible approach might be promising for future tailor-made local gene therapy in arthritis.
Keywords: Arthritis; Cytokines; Inflammation; Synovitis; Treatment.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Similar articles
-
Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis.Arthritis Rheum. 2005 Oct;52(10):3239-47. doi: 10.1002/art.21342. Arthritis Rheum. 2005. PMID: 16200598
-
Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction.J Immunol. 1999 Oct 15;163(8):4546-56. J Immunol. 1999. PMID: 10510398
-
Disease-Modifying Osteoarthritis Treatment With Interleukin-1 Receptor Antagonist Gene Therapy in Small and Large Animal Models.Arthritis Rheumatol. 2018 Nov;70(11):1757-1768. doi: 10.1002/art.40668. Epub 2018 Sep 10. Arthritis Rheumatol. 2018. PMID: 30044894
-
Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators.Rheum Dis Clin North Am. 2002 Feb;28(1):127-49. doi: 10.1016/s0889-857x(03)00073-5. Rheum Dis Clin North Am. 2002. PMID: 11840694 Review.
-
Gene therapy of arthritis.Intern Med. 1999 Mar;38(3):233-9. doi: 10.2169/internalmedicine.38.233. Intern Med. 1999. PMID: 10337932 Review.
Cited by
-
Biomimetic Scaffolds Modulate the Posttraumatic Inflammatory Response in Articular Cartilage Contributing to Enhanced Neoformation of Cartilaginous Tissue In Vivo.Adv Healthc Mater. 2022 Jan;11(1):e2101127. doi: 10.1002/adhm.202101127. Epub 2021 Oct 28. Adv Healthc Mater. 2022. PMID: 34662505 Free PMC article.
-
Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy.Cytotherapy. 2021 Nov;23(11):1017-1028. doi: 10.1016/j.jcyt.2021.05.010. Epub 2021 Aug 15. Cytotherapy. 2021. PMID: 34404616 Free PMC article.
-
Gene therapy for chondral and osteochondral regeneration: is the future now?Cell Mol Life Sci. 2018 Feb;75(4):649-667. doi: 10.1007/s00018-017-2637-3. Epub 2017 Sep 1. Cell Mol Life Sci. 2018. PMID: 28864934 Free PMC article. Review.
-
Ellagic acid alleviates adjuvant induced arthritis by modulation of pro- and anti-inflammatory cytokines.Cent Eur J Immunol. 2016;41(4):339-349. doi: 10.5114/ceji.2016.65132. Epub 2017 Jan 24. Cent Eur J Immunol. 2016. PMID: 28450796 Free PMC article.
-
The Protective Effect of Different Polar Solvent Extracts of Er Miao San on Rats with Adjuvant Arthritis.Evid Based Complement Alternat Med. 2020 Feb 20;2020:5305278. doi: 10.1155/2020/5305278. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32148544 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical